On 10 September 2026, LIFETECH SCI (01302.HK) announced that the LantvalTM aortic valve replacement system, the world's first sutureless system with a fully preloaded dry-valve design jointly developed with Fuwai Hospital, has entered the NMPA Innovative Medical Device Special Review Procedure, becoming the company's 18th product to do so.
On 9 September 2026, Jinxin Fertility Group Limited (01951.HK) announced in a voluntary announcement its proposal to develop a translational medicine platform focusing on women's health (initially targeting ovarian ageing and diminished ovarian reserve), leveraging its existing clinical and reproductive medicine capabilities; it has signed a research MOU with academician Professor Ji Weizhi and a framework agreement with a research animal resources partner, with the platform at an early stage and no material near-term impact expected.
On 9 September 2026, HBM Holdings Limited (02142.HK) announced in a voluntary announcement that its partner Solstice Oncology had completed a USD 225 million Series A financing led by RA Capital Management and commenced operations; Solstice is advancing the second-generation Fc-enhanced anti-CTLA-4 antibody pruluzubartamab, with a Phase II study in MSS colon cancer expected to begin enrolment in early Q4 2026.
On 9 September 2026, CSPC Pharmaceutical Group Limited (01093.HK) announced in a voluntary announcement that its rotigotine long-acting injection (SYH9087), a dopamine receptor agonist, had received NMPA approval for clinical trials in China, becoming the first subcutaneous rotigotine long-acting product cleared for clinical studies in China; the product is dosed once weekly without preparation, and the approved indication is Parkinson's disease.
On 9 September 2026, CSPC Pharmaceutical Group Limited (01093.HK) announced in a voluntary announcement that its goserelin extended-release injection (SYH9102), a GnRH receptor agonist, had received NMPA approval for clinical trials in China, becoming the world's first ready-to-use goserelin extended-release injection cleared for clinical studies; the product is dosed once monthly without preparation, showed superior castration rates and maintenance versus marketed microsphere formulations in preclinical studies, and the approved indication is solid tumours.
On September 9, 2026, the three major Hong Kong indices continued to weaken, with the Hang Seng Index down 0.17%, the Hang Seng TECH Index down 0.76%, and the Hang Seng China Enterprises Index down 0.34%. The large model sector showed divergent performance, the AI chip theme was under overall pressure, and intelligent driving saw mixed gains and losses.
On September 9, 2026, BIDU-W (09888.HK) traded firmly during the session. As of 13:39, it was quoted at HK$92.10, up 2.85%.
on September 9, 2026, the Hong Kong chip theme rose at the open, with ASMPT (00522.HK) opening higher and fluctuating. As of 13:31, the company was quoted at HK$166.400, up 3.10%.
on September 9, 2026, the robotics theme fluctuated and weakened, with XIAOMI-W (01810.HK) continuing to decline. As of 13:21, the company was quoted at HK$26.160, down 2.82%.
On 8 September 2026, HBM Holdings Limited (02142.HK) announced in a voluntary announcement that collaborator Windward Bio had reported positive interim results from the Phase II part of POLARIS-1 for anti-TSLP antibody HBM9378/WIN378 in asthma: at week 24, the placebo-adjusted mean increase in FEV1 reached up to 256 mL (p=0.033), with FeNO down 43% and EOS down 51%, and a half-life of up to 75 days supporting twice-yearly dosing; the Phase III part has been initiated, with POLARIS-2 planned for the first half of 2027.
On 8 September 2026, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (06990.HK) announced in a voluntary announcement that collaborator Windward Bio had reported positive interim results from the Phase II part of POLARIS-1 for anti-TSLP antibody SKB378/WIN378 in asthma (147 patients enrolled): at week 24, the placebo-adjusted mean increase in FEV1 reached up to 256 mL (p=0.033), with FeNO down 43% and EOS down 51%, and a half-life of up to 75 days supporting twice-yearly dosing; the Phase III part has been initiated.
On 8 September 2026, Sino Biopharmaceutical Limited (01177.HK) announced in a voluntary announcement that preclinical data of TQH5528, an oral STAT6 degrader independently developed by subsidiary Chia Tai-Tianqing Pharmaceutical Group, had been presented at ERS 2026, showing picomolar-level STAT6 degradation superior to comparator KT-621, significant STAT6 downregulation after a single dose in non-human primates, and improved airway hyperresponsiveness in a humanised asthma mouse model, with in vivo safety studies ongoing.
On 8 September 2026, CSPC Pharmaceutical Group Limited (01093.HK) announced in a voluntary announcement that its Category 1 innovative chemical drug SYH2083 Eye Drops had received clinical trial approval from the National Medical Products Administration for dry eye disease, with preclinical studies showing significant efficacy in a mouse dry eye model and potential expansion to allergic conjunctivitis and other inflammatory ocular surface diseases.
On 8 September 2026, FOSUN PHARMA (02196.HK) disclosed that its controlling subsidiary has obtained NMPA approval for FXS5626 (a TYK2/JAK1 dual-target inhibitor) to conduct Phase II/III trials in non-segmental vitiligo, with the Group holding exclusive rights in mainland China, Hong Kong and Macao and cumulative R&D investment of approximately RMB 108 million.
On September 8, 2026, the three major Hong Kong indices opened lower and fluctuated, with the Hang Seng Index down 0.38%, the Hang Seng TECH Index down 1.61%, and the Hang Seng China Enterprises Index down 0.38%. On that day, most AI concept stocks weakened, with the large model and AI chip sectors suffering heavy losses, while the intelligent driving theme saw mixed gains and losses.
On September 8, 2026, RoboSense (02498.HK) traded weaker in the afternoon session. As of 15:27, it was quoted at HK$17.62, down 2.44%.
